Eris Lifesciences released its Q3 and 9M FY26 investor presentation, reporting 10% growth in DBF revenue to Rs 696 crore in Q3 and Rs 2,106 crore in 9M, with EBIDTA margins near 37% and guidance for 12% FY26 DBF revenue growth.
AI Assistant
ERIS Lifesciences Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.